Single-Dose Oral Lacosamide in Refractory Simple Partial Status Epilepticus

Hawkes, Maximiliano A.; Suárez, Marcos Fernández; Ugarnes, Gabriela; D’Giano, Carlos

doi:10.1097/wnf.0b013e31829b21ba

Cited by 6 publications

(5 citation statements)

References 11 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional case reports hint at a positive effect of LCM in focal motor SE: Spalletti and colleagues describe a 39-year-old male with focal motor SE responsive to LCM as a fifth AED [Spalletti et al 2013]. Hawkes and colleagues describe two additional patients with focal motor SE responsive to oral LCM as adjunctive AED [Hawkes et al 2013]. A single case report suggests that LCM is effective in absence SE [Sodemann et al 2014], although this is contested [d'Orsi et al 2014].…”

Section: Use In Status Epilepticusmentioning

confidence: 99%

The efficacy of lacosamide as monotherapy and adjunctive therapy in focal epilepsy and its use in status epilepticus: clinical trial evidence and experience

Bauer

Willems

Paule

et al. 2016

Ther Adv Neurol Disord

View full text Add to dashboard Cite

Lacosamide (LCM) is approved for anticonvulsive treatment in focal epilepsy and exhibits its function through the slow inactivation of voltage-gated sodium channels (VGSCs). LCM shows comparable efficacy with other antiepileptic drugs (AEDs) licensed in the last decade: in three randomized placebo-controlled trials, significant median seizure reduction rates of 35.2% for 200 mg/day, 36.4-39% for 400 mg/day and 37.8-40% for 600 mg/day were reported. Likewise, 50% responder rates were 38.3-41.1% for 400 mg/day and 38.1-41.2% for 600 mg/day. Similar rates were reported in post-marketing studies. The main adverse events (AEs) are dizziness, abnormal vision, diplopia and ataxia. Overall, LCM is well tolerated and has no clinically-relevant drug-drug interactions. Due to the drug's intravenous availability, its use in status epilepticus (SE) is increasing, and the available data are promising.

show abstract

Section: Use In Status Epilepticusmentioning

confidence: 99%

The efficacy of lacosamide as monotherapy and adjunctive therapy in focal epilepsy and its use in status epilepticus: clinical trial evidence and experience

Bauer

Willems

Paule

et al. 2016

Ther Adv Neurol Disord

View full text Add to dashboard Cite

show abstract

“…Although LCM is not FDA approved for SE, it has been evaluated in this setting in multiple case series, case reports, and retrospective reviews . The populations studied varied in the types of SE encountered: generalized, convulsive, absence, focal, complex partial, nonconvulsive, refractory, and super refractory (Table ).…”

Section: Discussionmentioning

confidence: 99%

“…Earlier evidence regarding the use of LCM in SE was available as case reports, most of which were published shortly after LCM entered the market (Table ) …”

Section: Discussionmentioning

confidence: 99%

“…Earlier evidence regarding the use of LCM in SE was available as case reports, most of which were published shortly after LCM entered the market ( Table 5). [42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58] Several studies evaluated the dosing of LCM in SE. One prospective investigation 59 compared a 400-mg IV dose with a 200-mg dose after experiencing poor responses with the latter regimen in 25 patients with SE or RSE.…”

Section: Response After 30 Min Aes: None Reportedmentioning

confidence: 99%

See 1 more Smart Citation

Use of Newer Anticonvulsants for the Treatment of Status Epilepticus

et al. 2019

View full text Add to dashboard Cite

Status epilepticus (SE) has a high mortality rate and is one of the most common neurologic emergencies. Fast progression of this neurologic emergency and lack of response to traditional antiepileptic drugs (AEDs) in most cases has challenged clinicians to use new agents. This article evaluates the efficacy and safety of AEDs released to the market after 2000 for SE, refractory status epilepticus (RSE), and super‐refractory status epilepticus (SRSE). The PubMed database was searched for clinical trials published between January 2000 and July 2018 using the search terms status epilepticus, refractory status epilepticus, super refractory status epilepticus, brivaracetam, clobazam, cannabidiol, eslicarbazepine, lacosamide, perampanel, rufinamide, stiripentol, and zonisamide. Trials that evaluated these agents in adults with SE, RSE, and SRSE were included. Brivaracetam use was identified in two retrospective reviews with success rates of 27% and 57%. One unsuccessful case report of cannabidiol use in SE was found. Four clobazam studies were identified in SE and RSE with success rates ranging from 25–100%. No evidence for the use of eslicarbazepine and zonisamide was found. Using the search terms for lacosamide identified 38 articles: 1 systematic review, 5 prospective studies, 15 retrospective reviews, and 17 case reports. Success rates and dosing varied, but studies that included focal or partial types of SE showed higher success rates. Five articles were identified regarding perampanel use in this setting. Three were retrospective reviews with success rates ranging from 17–60%, and two were case reports. Only one case report regarding the use of rufinamide was found; rufinamide titrated up to 4.4 mg/day allowed discontinuation of barbiturate and clobazam. One case report and two case series of stiripentol were found with reported efficacy between 60% and 100% in SRSE. Evidence is currently insufficient to support the use of these agents in this setting.

show abstract

“…Furthermore, several case reports have been reported (Table ). Hawkes et al described two patients with refractory focal motor SE responsive to a single oral dose of 300 mg LCM as adjunctive AED. LCM was given as the third or fourth AED, respectively.…”

Section: Use Of Lcm In Adults With Status Epilepticusmentioning

confidence: 99%